We focus on exploring glycans as powerful biomarkers. These complex sugar molecules undergo significant alterations during disease progression, often preceding detectable DNA or protein modifications. Our accurate glycan characterization enables researchers to uncover new biomarkers for early disease detection and treatment monitoring.
ISOSPEC's technology addresses critical challenges in molecular characterization across biopharmaceuticals, nutrition, and agriculture. Our platform enables detailed glycan profiling for optimizing monoclonal antibodies, analyzes fermentation products, and supports metabolite identification for product development and safety assessments.
Having secured a 2 million CHF seed round, we're scaling our workflows and advancing our analysis capabilities. ISOSPEC seeks partnerships to transform glycomic/metabolomic data into actionable clinical insights, improving human health through a deeper understanding of the glycomic/metabolomic basis of disease.